Histone Deacetylase Inhibitors Market By Class 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Histone Deacetylase Inhibitors Market
Histone Deacetylase Inhibitors Market: By Class (Class I, Class II, Class III); By Application (Oncology, Neurology and Others) and By Geography (Asia-Pacific, Europe, North America and RoW) -Forecast (2016-2021)
Report Code : HCR 0220
Updated Date: 01 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Histone deacetylase inhibitors are a class of compounds that interfere with the function of histone deacetylase. They are the enzymes which remove acetyl groups from an N-acetyl lysine amino acid present on a histone, thus wrapping the DNA tightly by the histones.

Globally, an increase in the number of cancer patients across the globe and the need to improve effectiveness of new therapies are the prime growth drivers of histone deacetylase inhibitors market. Additionally, increased R&D activities being carried out for the treatment of cancers & other diseases and increase in collaborations and investments in the HDAC manufacturing are proving to be the major opportunities for the growth of this market. However, reimbursement and uncertainty issues in regards to HDAC inhibitors are the key restraints for the histone deacetylase inhibitors market.

This report identifies the global Histone Deacetylase Inhibitors Market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to Histone Deacetylase Inhibitors Market.
 
Histone Deacetylase Inhibitors Market

Geographically, Asia-Pacific dominates the Histone Deacetylase Inhibitors Market, and is projected to have the fastest growth. North America, Europe and Rest of the World (RoW) follow Asia-Pacific in terms of market volume. Oncology is expected to be the fastest growing application segment in the global histone deacetylase inhibitors market.

This report segments Histone Deacetylase Inhibitors market on the By Application, By Class and By Geography as follows:
  • Histone Deacetylase Inhibitors Market, By Class: Class I HDAC, Class II HDAC, Class III HDAC and Others
  • Histone Deacetylase Inhibitors Market, By Application: Neurology, Oncology and Others
  • This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region. The major countries considered under the Asia-Pacific region are India, China, South Korea and Japan. The major countries considered under the European region are Germany, U.K., France, Italy, Spain and Russia. The major countries considered under the North American region are United States, Canada and Mexico.

This report identifies all the major companies operating in the Histone Deacetylase Inhibitors market. Some of the major companies’ profiles in detail are as follows:
  • Celgene Corporation
  • Novartis International AG
  • AstraZeneca PLC
  • Acetylon Pharmaceuticals
  • Envivo Pharmaceuticals
1. Histone Deacetylase Inhibitors Market – Overview
2. Executive Summary
3. 
Histone Deacetylase Inhibitors Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Histone Deacetylase Inhibitors Market–Forces
   4.1. Drivers
      4.1.1. Increase in the number of cancer patients across the globe
      4.1.2. Need to improve effectiveness of new therapies
   4.2. Restraints
      4.2.1. Reimbursement and uncertainty issues
   4.3. Opportunities
      4.3.1. Increased R&D activities being carried out for the treatment of cancers and other diseases
      4.3.2. Increase in collaborations and investments in the HDAC manufacturing
   4.4. Porter’s Five Forces Analysis
      4.4.1. Bargaining Power of Suppliers
      4.4.2. Bargaining Power of Buyers
      4.4.3. Threat of New Entrants
      4.4.4. Threat of Substitutes
      4.4.5. Degree of Competition
5. Histone Deacetylase Inhibitors Market, By Class
   5.1. Class I HDAC
   5.2. Class II HDAC
   5.3. Class III HDAC and
   5.4. Others
6. Histone Deacetylase Inhibitors Market, By Application
   6.1. Oncology
   6.2. Neurology and
   6.3. Others
7. Histone Deacetylase Inhibitors Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Histone Deacetylase Inhibitors – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
   9.1. Merck & Co., Inc.
   9.2. Celgene Corporation
   9.3. Novartis International AG
   9.4. Celleron Therapeutics
   9.5. Envivo Pharmaceuticals
   9.6. AstraZeneca PLC
   9.7. Acetylon Pharmaceuticals
   9.8. Pfizer
   9.9. Eisai Pharmaceuticals
   9.10. Cellceutix Corporation
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix
   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll